DarioHealthDRIO +7.85%58 Days Payable is 122.41 as of Mar. 2026, which is 4% below its 10-year median of 127.98. GuruFocus rates DRIO with a GF Score™ of 58/100 and a GF Value™ of $7.09 (Fairly Valued). The stock has 4 warning signs investors should review. Among 607 Healthcare Providers & Services companies, DarioHealth ranks better than 75.45% on this metric.
The historical rank and industry rank for DarioHealth's Days Payable or its related term are showing as below:
DRIO'
s Days Payable Range Over the Past 10 Years
Min: 43.86 Med: 127.98 Max: 173.28
Current: 126.76
During the past 13 years, DarioHealth's highest Days Payable was 173.28. The lowest was 43.86. And the median was 127.98.
DRIO's Days Payable is ranked better than 75.45% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs DRIO: 126.76
DarioHealth's Days Payable
increased
from Mar. 2025 (92.04) to Mar. 2026 (122.41).
It may suggest that DarioHealthdelayed paying its suppliers.
DarioHealth Days Payable Related Terms
DarioHealth Days Payable Historical Data
* Premium members only.
The historical data trend for DarioHealth's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, DarioHealth's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DarioHealth Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's Days Payable distribution charts can be found below:
* The bar in red indicates where DarioHealth's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
DarioHealth's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DarioHealth (DRIO) has a Days Payable of 122.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DarioHealth and its competitors. This is near median its historical median of 127.98. Over the past decade, DarioHealth's Days Payable has ranged from 43.86 to 173.28. According to the industry distribution chart, DarioHealth ranks #149 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 24.5%.
Is DarioHealth's Days Payable too high?
DarioHealth's current Days Payable of 122.41 is near median its 10-year median of 127.98. Over the past 10 years, this metric has ranged from a low of 43.86 to a high of 173.28. The Healthcare Providers & Services industry median Days Payable is 58.00. DarioHealth's value of 122.41 is 111.1% above this industry median. Based on the distribution chart, DarioHealth ranks #149 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DarioHealth has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's Days Payable compare to BEAT and ONMD?
According to the Healthcare Providers & Services industry distribution chart, DarioHealth ranks #149 out of 607 companies for Days Payable. This places DarioHealth in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.00. DarioHealth's value of 122.41 is 111.1% above this benchmark. Historically, DarioHealth's own Days Payable has ranged from 43.86 to 173.28 over the past decade. While the company's 10-year median is 127.98 vs. the industry median of 58.00, DarioHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DarioHealth's current Days Payable of 122.41 is 111.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DarioHealth and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DarioHealth's current Days Payable is 122.41, which is near median its own 10-year median of 127.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Fairly Valued. The stock's GF Value™ is $7.09, compared to a current price of $7.26 — trading 2.3% above its estimated fair value. The current Days Payable is 122.41, which is near median its 10-year median of 127.98 and 111.1% above the Healthcare Providers & Services industry median of 58.00. DarioHealth's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For DarioHealth (DRIO), the current Days Payable is 122.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DarioHealth (DRIO) Overvalued in 2026?
Based on GuruFocus' analysis, DarioHealth stock appears to be overvalued.
The current stock price of $7.26 is trading 2.3% above its estimated GF Value™ of $7.09.
GuruFocus considers DarioHealth to be Fairly Valued.
Key valuation signals for DRIO:
Days Payable: 122.41 (near median its 10-year median of 127.98)
GF Value™: $7.09 vs. price of $7.26 (2.3% above fair value)
Industry Position: 111.1% above the Healthcare Providers & Services median (#149 of 607)
No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
58GF Score
Get the complete analysis for DRIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRIO has been successfully added to your 
